DDInter32 DDInter1752
Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test. Gilotrif (afatinib) is the first FDA-approved oncology product from Boehringer Ingelheim.
Drug-resistant bacteria, such as methicillin-resistant _Staphylococcus aureus_, vancomycin-resistant _Enterococcus faecium_, and penicillin-resistant _Streptococcus penumoniae_, represent a massive public health threat.[A199086, A199131] Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved [linezolid] and is generally effective against multidrug-resistant Gram-positive bacteria. Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and is generally more effective and more tolerable than [linezolid].[L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®). This product is currently available as both an oral tablet and as a powder for intravenous injection.
Afatinib {u} (Compound) resembles {v} (Compound) Gefitinib
Afatinib {u} (Compound) binds {v} (Gene) ABCB1
Afatinib {u} (Compound) upregulates {v} (Gene) MTHFD2
Afatinib {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Afatinib {u} (Compound) downregulates {v} (Gene) IGFBP2
Afatinib {u} (Compound) causes {v} (Side Effect) Diarrhoea
Afatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fosphenytoin
Afatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glasdegib
Afatinib {u} may lead to a major life threatening interaction when taken with {v} Lomitapide
Afatinib {u} (Compound) binds {v} (Gene) and {u} (Compound) downregulates {v} (Gene) ERBB2
Afatinib (Compound) resembles Gefitinib (Compound)
Afatinib (Compound) binds ABCB1 (Gene)
Afatinib (Compound) upregulates MTHFD2 (Gene)
Afatinib (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class)
Afatinib (Compound) downregulates IGFBP2 (Gene)
Afatinib (Compound) causes Diarrhoea (Side Effect)
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Afatinib may lead to a major life threatening interaction when taken with Lomitapide
Afatinib (Compound) binds ERBB2 (Gene) and Afatinib (Compound) downregulates ERBB2 (Gene)